High sensitivity troponin outperforms contemporary assays in predicting major adverse cardiac events up to two years in patients with chest pain
Authors:
- 25 March 2011
- journal article
- research article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 48 (3) , 249-255
Abstract
Background: Previous studies have shown a risk of subsequent major adverse cardiovascular events (MACEs) in patients with suspected acute coronary syndromes (ACSs) and elevated cardiac troponin. The aim of this study was to compare prognostic utility of high-sensitivity troponin with contemporary troponin assays in such patients. Methods: In total, 332 patients with suspected ACS were investigated between November 2006 and April 2007; all were followed for two years. Blood samples were analysed to compare Roche Elecsys high-sensitivity troponin T (hsTnT), Abbott Architect troponin I 3rd generation (TnI 3) and Roche Elecsys troponin T (TnT), for the prediction of MACE (composite of cardiovascular death, non-fatal myocardial infarction and revascularization). Results: Sixty-eight patients (20.5%) experienced MACE between discharge and two years. Receiver operating characteristic (ROC) curve derived area under the ROC curve (95% confidence intervals) for baseline hsTnT were 0.70 (0.63–0.76), TnI 3 0.66 (0.59–0.73) and TnT 0.61 (0.53–0.69). hsTnT ( P = 0.001) was superior to TnT and TnI 3 trended ( P = 0.094) to superiority but were equivalent to each other. hsTnT best stratified patients with cumulative event rates for two-year MACE of 35.6% for levels ≥99th percentile, 17.9% for levels between the limit of detection (LOD) and 99th percentile and 5.4% for levels <LOD compared with TnI 3: 33.0%, 31.1% and 10.9%, respectively. TnT had MACE rates of 36.7% when ≥99th percentile and 15.4% when <99th percentile (=LOD). Conclusions: hsTnT outperformed contemporary TnI and TnT assays for the prediction of MACE at two years. Those with levels below the LOD for hsTnT identified a group of patients at very low risk for adverse events.Keywords
This publication has 25 references indexed in Scilit:
- Evaluation of High-Sensitivity Assays for Cardiac TroponinClinical Chemistry, 2009
- Clinical Performance of Two Highly Sensitive Cardiac Troponin I AssaysClinical Chemistry, 2009
- Will new higher-precision troponins lead to clarity or confusion?Current Opinion in Cardiology, 2008
- Use of the bioMérieux VIDAS® troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndromeClinica Chimica Acta, 2008
- Use of the Centaur TnI-Ultra Assay for Detection of Myocardial Infarction and Adverse Events in Patients Presenting With Symptoms Suggestive of Acute Coronary SyndromeClinical Chemistry, 2008
- Use and interpretation of cardiac troponins in the EDThe American Journal of Emergency Medicine, 2008
- Universal Definition of Myocardial InfarctionJACC, 2007
- Usefulness of Troponin Levels Below the Diagnostic Cut-Off Level for Acute Myocardial Infarction in Predicting Prognosis in Unselected Patients Admitted to the Coronary Care UnitThe American Journal of Cardiology, 2007
- Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial InfarctionClinical Chemistry, 2005
- Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy)The American Journal of Cardiology, 2002